| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-2952(93)90310-S |
| P698 | PubMed publication ID | 8484807 |
| P50 | author | David J. Waxman | Q30506493 |
| P2093 | author name string | G F Weber | |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1685-1694 | |
| P577 | publication date | 1993-04-01 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes | |
| P478 | volume | 45 |
| Q36291998 | 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity |
| Q44351300 | Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. |
| Q35058030 | Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications |
| Q51693639 | Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. |
| Q32117273 | Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites |
| Q33639790 | Cytochrome P450-based cancer gene therapy: recent advances and future prospects |
| Q40040755 | Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS. |
| Q84589457 | Differential cytotoxicity of Ifosfamide and its metabolites in renal epithelial cell cultures |
| Q77314596 | Differential in vitro hepatic and intestinal metabolism of ifosfamide in the rat |
| Q40297694 | Enantioselective metabolism of ifosfamide by the kidney |
| Q43790044 | Gender difference in ifosfamide metabolism by human liver microsomes |
| Q34176439 | Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives |
| Q35745249 | Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms |
| Q44237367 | Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer |
| Q77711295 | In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide |
| Q41702059 | Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach |
| Q35172242 | Interactions between antiepileptic and chemotherapeutic drugs |
| Q54449378 | Lack of effect of methotrexate on the expression of constitutive hepatic cytochromes P450 in the male rat. |
| Q34749403 | Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo |
| Q37386327 | Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors |
| Q42548269 | Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells |
| Q44124151 | Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene |
| Q58483640 | Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide |
| Q37361514 | Stereoselective pharmacokinetics of ifosfamide in male and female rats |
| Q40253486 | Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. |
| Q36292157 | The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study |
| Q43824466 | cAMP-dependent phosphorylation of CYP2B1 as a functional switch for cyclophosphamide activation and its hormonal control in vitro and in vivo. |
Search more.